Tempest Therapeutics (NASDAQ: TPST) — Company Overview, News & Financial Data
Tempest Therapeutics develops small molecule therapeutics targeting cancer biology and inflammation to address unmet medical needs.
Tempest Therapeutics
Tempest Therapeutics (NASDAQ:TPST) is focused on discovering and developing a diverse portfolio of small molecule therapeutics. Their work is dedicated to addressing a wide range of diseases with significant unmet medical needs. Central to their operations are innovative projects aimed at targeting key pathways in cancer biology, immune-oncology, and inflammation. By leveraging cutting-edge science, Tempest aims to advance these therapeutics from conception through clinical development, with the objective of bringing transformative treatments to patients worldwide. Their commitment to research and development underscores a broader mission to improve healthcare outcomes and enhance the quality of life for patients grappling with serious diseases.
Snapshot
Operations
Products and/or services of Tempest Therapeutics
- TPST-1120, a selective PPARa antagonist aimed at treating various cancers by targeting tumor and immune cells.
- TPST-1495, a dual EP2/EP4 antagonist for solid tumors, enhancing antitumor immunity.
- Preclinical programs focusing on novel targets in immuno-oncology to stimulate the immune system against cancer.
- Collaboration projects for the development and commercialization of proprietary oncology therapies.
- Research initiatives to identify and validate next-generation targets in cancer therapy.
Tempest Therapeutics executive team
- Matthew AngelPresident, CEO & Director
- Constance AmesCFO, Principal Financial & Accounting Officer, Treasurer, and Corporate Secretary
- Andrew FangHead of Business Development
Latest news about Tempest Therapeutics
Key financials
Reported results for Tempest Therapeutics, in USD.
- Market cap
- 9.4M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -3.9
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -26.6M | -26.3M | |
| 0 | -42M | -41.8M | |
| 0 | -29.2M | -29.5M | |
| 0 | -34.6M | -35.7M |